Skip to main content

NOVO NORDISK A/S & ANR vs. SAJJALA BIO LABS PRIVATE LIMITED. CS (COMM) 394/2019

A suit was filed seeking a permanent injunction restraining infringement of suit patent nos. 257402 and 257528. The Plaintiff alleged that the suit patents related to a novel and unique formulation of the molecule ‘LIRAGLUTIDE’ and a process thereof. On acquiring knowledge that the Defendant was planning to launch ‘LIRAGLUTIDE’ in a formulation that would be infringing the Plaintiff’s patents, the suit was filed seeking a permanent injunction and other reliefs.

On 2 August 2019, the Defendant entered appearance and sought time. In the interregnum, the parties explored an amicable resolution in view of the stand taken by the Defendant.

Ld. Counsel for the Defendant further submitted that it was not the intention of the Defendant to infringe upon any of the suit patents being IN 257402 and IN 257528.

Accordingly, the Plaintiff, upon the Defendant’s assurances, did not press for rendition of accounts or other reliefs so long as the undertaking of the Defendant was recorded that they shall not infringe the suit patents IN 257402 and IN 257528.

On 6 August 2019, the Hon’ble High Court of Delhi decreed the suit on the basis of the following terms and conditions which were mutually agreed upon by the parties:

  • That the Defendant undertakes not to manufacture, use, offer for sale or sell any formulation of ‘LIRAGLUTIDE’ or use a process for manufacture thereof, which constitutes an infringement of Suit patent nos. IN 257402 and IN 257528;
  • The above undertaking shall not in any manner preclude the Defendant from manufacture or sale of the API ‘LIRAGLUTIDE’ so long as the same is a non-infringing formulation or process;
  • In view of the above undertakings given by the Defendant, the Plaintiff does not press for the relief of rendition of accounts or damages;
  • The Defendant assures the Court that it does not have any stock of infringing ‘LIRAGLUTIDE’ products.

Further, in view of the suit having been settled at the inception itself, 50% of the Court fee was directed to be refunded to the Plaintiff.

While there may be cases with a pressing lack for speedy disposal but decrees such as these demonstrate how depending on resolution efforts, matters may be promptly disposed of.

Team Anand and Anand: Pravin Anand, Archana Shanker, Dhruv Anand, Udita M Patro and Kavya Mammen.

Most Recent

News & Insights

VIEW ALL
News & Updates
Aug 25, 2025

At the FICCI–ICRIER Conference on SEPs (23rd August 2025), our Managing Partner Mr. Pravin Anand shared his vision on how India can evolve from being

Conference on Standard Essential Patents (SEPs)
News & Updates
Aug 24, 2025

‘Intellectual Property for a company/ creator is as critical and important as human rights for an individual,’ this guiding belief at ANAND AND ANAND

IAM Strategy 300
Thought Leadership
Aug 21, 2025

‘First published on IAM’ By:  Vaishali R Mittal Patent examination by the Indian Patent Office (IPO) has slowed down dramatically over the last few

Patent examination slowdown risks harming India’s IP momentum
Thought Leadership
Jul 28, 2025

‘First published on Asia IP’ By: Pravin Anand In the book What is Life, written in 1944 by theoretical physicist Erwin Schrödinger, the author states: “A

Human versus machine consciousness